IMM
ImmuPharma Plc
Latest RNS
Powered by Vox Markets
- Immupharma PLC - Update on Nucant Cancer Programme
- Immupharma PLC - Corporate Update
- Immupharma PLC - Technology review published-Nature Communications
- Immupharma PLC - Clinical Development Collaboration with Incanthera
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Appointment of Nominated Adviser
- Immupharma PLC - Update on Corporate Activities
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Nominated Adviser Status
- Immupharma PLC - Interim Results
- Immupharma PLC - Appointment of Joint Brokers
- Immupharma PLC - Corporate Update
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Result of AGM
- Immupharma PLC - Results of CIDP Pre-Clinical Data
- Immupharma PLC - Notice of AGM & Posting of Annual Report
- Immupharma PLC - Final Results
- Immupharma PLC - Update on Pivotal Phase III Trial of Lupuzor
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Topline results of Lupuzor Pivotal Phase III Trial
- Immupharma PLC - Appointment of Joint Broker
- Immupharma PLC - Lupuzor Pivotal Phase III Study Update
- Immupharma PLC - AIM Notice (17)
- Immupharma PLC - Grant of Options
- Immupharma PLC - Last patient completes dosing in LupuzorT Trial
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Grant of Options
- Immupharma PLC - Update on LupuzorT Pivotal Phase III Study
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Completion of Lanstead Sharing Agreement
- Immupharma PLC - Interim Results
- Immupharma PLC - Preparation of Lupuzor'sT Regulatory Submissions
- Immupharma PLC - Update on LupuzorT Pivotal Phase III Study
- Immupharma PLC - Notification of Interim Results
- Immupharma PLC - AIM Rule 17 Notice
- Immupharma PLC - Grant of Options
- Immupharma PLC - Result of AGM
- Immupharma PLC - Update on LupuzorT Pivotal Phase III Study
- Immupharma PLC - Annual Report & Notice of AGM
- Immupharma PLC - Final Results
- Immupharma PLC - Notification of Full Year Results
- Immupharma PLC - Update on Lupuzor Phase III Study
- Immupharma PLC - New Employee Share Option Plan & Grant of Options
- Immupharma PLC - New Employee Share Option Plan & Grant of Options
- Immupharma PLC - ImmuPharma to present at Master Investor Show
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - £4.1 Million Fund Raise via Accelerated Bookbuild
- Immupharma PLC - Accelerated Bookbuild for the Issue of Equity
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Update on Lupuzor Phase III Study
- Immupharma PLC - Change of Adviser
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Update on Lupuzor Pivotal Phase III Study
- Immupharma PLC - Update on Cancer Compound IPP-204106 'Nucant'
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Close of Accelerated Bookbuild
- Immupharma PLC - Proposed Accelerated Bookbuild for Vendor Placing
- Immupharma PLC - Half-year Report
- Immupharma PLC - UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
- Immupharma PLC - UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Appointment of Joint Broker
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Symposium with Lupuzors Inventor Prof. S Muller
- Immupharma PLC - European Patients Commence Dosing in Lupuzor
- Immupharma PLC - Director/PDMR Shareholding
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Result of AGM
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Annual Financial Report & Notice of AGM
- Immupharma PLC - Final Results
- Immupharma PLC - Notice of Results
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - First European Site Opens - Patient Recruitment
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - EIS and VCT Qualifying Status and Issue of Equity
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Issue of Equity
- Immupharma PLC - Result of GM
- Immupharma PLC - US PATIENTS COMMENCE DOSING IN PHASE III STUDY
- Immupharma PLC - Placing and Subscription Raises £8.3 million
- Immupharma PLC - Proposed Placing and Subscription
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - ImmuPharma & Simbec-Orion - Investigators Meeting
- Immupharma PLC - Update on the progress of Lupuzor
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Lupuzor Phase III Pivotal Trial Update
- Immupharma PLC - Lupuzor Phase III Pivotal Trial Update
- Immupharma PLC - Directorate Change
- Immupharma PLC - Directorate Change
- Immupharma PLC - Interim Results
- Immupharma PLC - Richard Warr
- Immupharma PLC - TERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
- Immupharma PLC - Lupuzor's Founder Dr Slyviane Muller Awarded Medal
- Immupharma PLC - Result of AGM
- Immupharma PLC - Annual Report & Accounts
- Immupharma PLC - Interim Board Change
- Immupharma PLC - Directorate Change
- Immupharma PLC - Preliminary Results
- Immupharma PLC - Enterprise Investment Scheme Status
- Immupharma PLC - Collaboration Agreement with Simbec-Orion
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Additional Listing - Conditional Placing
- Immupharma PLC - ImmuPharma awarded EUR400,000 Grant
- Immupharma PLC - Half Yearly Report
- Immupharma PLC - LupuzorT Gears Up To Start Pivotal Phase III trial
- Immupharma PLC - Result of AGM
- Immupharma PLC - Access to pioneering research in Bordeaux France
- Immupharma PLC - NEW NUCANT PATENTS
- Immupharma PLC - Annual Financial Report
- Immupharma PLC - Preliminary Results
- Immupharma PLC - Dr. Sylviane Muller - Presentation Abstract
- Immupharma PLC - Dr. S Muller, founder of Lupuzor presentation.